Donald Milligan
About
Donald Milligan is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Donald Milligan has authored 99 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Hematology, 37 papers in Genetics and 26 papers in Molecular Biology. Recurrent topics in Donald Milligan's work include Acute Myeloid Leukemia Research (39 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Chronic Myeloid Leukemia Treatments (22 papers). Donald Milligan is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Chronic Myeloid Leukemia Treatments (22 papers). Donald Milligan collaborates with scholars based in United Kingdom, France and Denmark. Donald Milligan's co-authors include Keith Wheatley, Alan K. Burnett, Robert K. Hills, Anthony H. Goldstone, Nigel H. Russell, Chris Fegan, Lars Kjeldsen, Charles Craddock, Suparno Chakrabarti and Ann Hunter and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.
In The Last Decade
Donald Milligan
98 papers receiving 6.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Donald Milligan United Kingdom | 40 | 4.5k | 2.1k | 2.0k | 1.6k | 1.3k | 99 | 6.7k | ||
| Joseph O. Moore United States | 42 | 3.3k 0.7× | 1.5k 0.7× | 1.8k 0.9× | 1.9k 1.2× | 1.2k 0.9× | 148 | 6.6k | ||
| Vinod Pullarkat United States | 38 | 3.8k 0.8× | 1.4k 0.6× | 1.9k 1.0× | 1.2k 0.7× | 1.3k 1.0× | 228 | 6.0k | ||
| Aristoteles Giagounidis Germany | 49 | 8.5k 1.9× | 3.7k 1.7× | 3.4k 1.7× | 1.2k 0.7× | 1.5k 1.1× | 259 | 10.3k | ||
| Ulrich Germing Germany | 37 | 5.4k 1.2× | 2.4k 1.1× | 2.4k 1.2× | 804 0.5× | 971 0.7× | 252 | 7.0k | ||
| Bruno Varet France | 37 | 4.1k 0.9× | 2.6k 1.2× | 1.7k 0.8× | 1.4k 0.9× | 445 0.3× | 145 | 7.6k | ||
| Thomas R. Chauncey United States | 50 | 7.8k 1.8× | 2.2k 1.0× | 872 0.4× | 2.7k 1.6× | 1.7k 1.3× | 167 | 9.6k | ||
| Norbert Claude Gorin France | 45 | 4.4k 1.0× | 1.5k 0.7× | 926 0.5× | 1.9k 1.1× | 1.5k 1.2× | 188 | 6.9k | ||
| Gabriela Rondón United States | 41 | 4.7k 1.0× | 1.2k 0.6× | 850 0.4× | 2.3k 1.4× | 1.2k 0.9× | 254 | 7.0k | ||
| Ghulam Mufti United Kingdom | 27 | 4.7k 1.1× | 2.0k 0.9× | 1.2k 0.6× | 818 0.5× | 790 0.6× | 101 | 5.8k | ||
| F Bauters France | 45 | 5.2k 1.2× | 3.0k 1.4× | 2.6k 1.3× | 1.4k 0.8× | 721 0.6× | 211 | 7.3k |
Countries citing papers authored by Donald Milligan
Since
Specialization
Citations
This map shows the geographic impact of Donald Milligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Milligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Milligan more than expected).
Fields of papers citing papers by Donald Milligan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Donald Milligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Milligan. The network helps show where Donald Milligan may publish in the future.
Co-authorship network of co-authors of Donald Milligan
This figure shows the co-authorship network connecting the top 25 collaborators of Donald Milligan. A scholar is included among the top collaborators of Donald Milligan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald Milligan. Donald Milligan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pardanani, Animesh, Claire Harrison, Jörge E. Cortes, et al.. (2015). Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology. 1(5). 643–643.
2.
Knapper, Steven, Robert K. Hills, James D. Cavenagh, et al.. (2014). A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience. Blood. 124(21). 3736–3736.
3.
Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2013). Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. Journal of Clinical Oncology. 31(27). 3360–3368.
4.
Mesa, Ruben A., Jörge E. Cortes, Francisco Cervantes, et al.. (2013). Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA). Blood. 122(21). 4061–4061.
5.
Burnett, Alan K., Nigel H. Russell, Dominic Culligan, et al.. (2012). The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML . British Journal of Haematology. 158(4). 519–522.
6.
Burnett, Alan K., Robert K. Hills, Ann E. Hunter, et al.. (2011). The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. Blood. 118(21). 582–582.
7.
Burnett, Alan K., Donald Milligan, Anthony P. Goldstone, et al.. (2009). The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology. 145(3). 318–332.
8.
Wheatley, Keith, Cassandra Brookes, Andrew Howman, et al.. (2009). Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. British Journal of Haematology. 145(5). 598–605.
9.
Milligan, Donald, Keith Wheatley, Timothy J. Littlewood, Jenny I. O. Craig, & Alan K. Burnett. (2006). Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 107(12). 4614–4622.
10.
Campbell, Peter J., Linda M. Scott, Georgina Buck, et al.. (2005). Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. The Lancet. 366(9501). 1945–1953.
11.
Dreger, Peter, Anja van Biezen, Marc Boogaerts, et al.. (2005). Treatment-Related MDS/AML after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL): An EBMT Survey.. Blood. 106(11). 1122–1122.
12.
Starczynski, Jane, Chris Pepper, Guy Pratt, et al.. (2005). Common Polymorphism G(-248)A in the Promoter Region of the bax Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated. Journal of Clinical Oncology. 23(7). 1514–1521.
13.
Chakrabarti, Suparno, Donald Milligan, Paul Moss, & Vivien Mautner. (2004). Adenovirus Infections in Stem Cell Transplant Recipients: Recent Developments in Understanding of Pathogenesis, Diagnosis and Management. Leukemia & lymphoma. 45(5). 873–885.
14.
Aleem, Aamer, et al.. (2004). Performing Bone Marrow Harvest on an Outpatient Basis: A Single Center UK Experience. Acta Haematologica. 112(4). 200–202.
15.
Burnett, Alan K., Donald Milligan, Robert K. Hills, et al.. (2004). Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials.. Blood. 104(11). 1794–1794.
16.
Chakrabarti, Suparno, Vivien Mautner, Husam Osman, et al.. (2002). Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 100(5). 1619–1627.
17.
Chakrabarti, Suparno, Irit Avivi, Stephen Mackinnon, et al.. (2002). Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortality. British Journal of Haematology. 119(4). 1125–1132.
18.
Chakrabarti, Suparno, et al.. (2001). WILL MIXED CHIMERISM CURE AUTOIMMUNE DISEASES AFTER A NONMYELOABLATIVE STEM CELL TRANSPLANT?. Transplantation. 72(2). 340–342.
19.
Milligan, Donald, M C Ruiz de Elvira, Hans‐Jochem Kolb, et al.. (1999). Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. British Journal of Haematology. 106(4). 1020–1026.
20.
Lumley, Matthew, et al.. (1997). Colony counting is a major source of variation in CFU‐GM results between centres. British Journal of Haematology. 97(2). 481–484.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Joseph O. Moore Breakdown of academic impact, for papers by Vinod Pullarkat Breakdown of academic impact, for papers by Aristoteles Giagounidis Breakdown of academic impact, for papers by Ulrich Germing Breakdown of academic impact, for papers by Bruno Varet Breakdown of academic impact, for papers by Thomas R. Chauncey Breakdown of academic impact, for papers by Norbert Claude Gorin Breakdown of academic impact, for papers by Gabriela Rondón Breakdown of academic impact, for papers by Ghulam Mufti Breakdown of academic impact, for papers by F Bauters